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1 |  INTRODUCTION
Chronic kidney disease (CKD) affects ~15% of the popula-
tion. In many affected individuals, there is progression to end-
stage kidney disease (ESKD) leading to kidney failure and a 
need for dialysis and transplantation. Although a broad range 
of insults can initiate kidney injury, interstitial fibrosis is a 
final common pathologic mechanism of most causes of pro-
gressive CKD. Studies in animal models and humans support 
the conclusion that the degree of interstitial fibrosis and tu-
bular atrophy is strongly correlated with the severity of CKD 
in diverse forms of kidney disease (Klahr & Morrissey, 2002; 
DOI: 10.14814/phy2.14329  
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Abstract
Fibrosis is a final common pathway for many causes of progressive chronic kidney 
disease (CKD). Arginine–glycine–aspartic acid (RGD)-binding integrins are im-
portant mediators of the pro-fibrotic response by activating latent TGF-β at sites of 
injury and by providing myofibroblasts information about the composition and stiff-
ness of the extracellular matrix. Therefore, blockade of RGD-binding integrins may 
have therapeutic potential for CKD. To test this idea, we used small-molecule peptid-
omimetics that potently inhibit a subset of RGD-binding integrins in a murine model 
of kidney fibrosis. Acute kidney injury leading to fibrosis was induced by admin-
istration of aristolochic acid. Continuous subcutaneous administration of CWHM-
12, an RGD integrin antagonist, for 28 days improved kidney function as measured 
by serum creatinine. CWHM-12 significantly reduced Collagen 1 (Col1a1) mRNA 
expression and scar collagen deposition in the kidney. Protein and gene expression 
markers of activated myofibroblasts, a major source of extracellular matrix deposi-
tion in kidney fibrosis, were diminished by treatment. RNA sequencing revealed 
that inhibition of RGD integrins influenced multiple pathways that determine the 
outcome of the response to injury and of repair processes. A second RGD integrin 
antagonist, CWHM-680, administered once daily by oral gavage was also effective 
in ameliorating fibrosis. We conclude that targeting RGD integrins with such small-
molecule antagonists is a promising therapeutic approach in fibrotic kidney disease.
K E Y W O R D S
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Lee, Kim, & Choi, 2015), even after adjusting for eGFR, pro-
teinuria, and clinicopathological diagnosis (Srivastava et al., 
2018). Thus, targeting pro-fibrotic pathways is an important 
strategy to slow the progression of CKD. However, with the 
exception of renin–angiotensin (RAAS) blockers for treat-
ment of glomerular diseases, there are currently no specific 
therapies to ameliorate fibrosis and slow the decline in renal 
function. Moreover, while RAAS blockers slow the progres-
sion of proteinuric renal diseases, they do not arrest the dis-
ease or prevent the progression to end-stage kidney failure. 
Therefore, the development of new therapies for CKD is an 
important priority in the field.
Acute kidney injury (AKI) affects ~8%–16% of pa-
tients admitted to a hospital (Sawhney & Fraser, 2017). 
Epidemiological studies have documented an apparent rise in 
the population incidence of AKI and acute dialysis. This is 
an important public health concern because in addition to the 
high mortality associated with AKI, recent studies point to the 
serious long-term sequelae of CKD and dependence on renal 
replacement therapy for AKI survivors. AKI is a significant 
risk factor for postrecovery fibrosis and progressive CKD 
(Chawla & Kimmel, 2012). AKI is associated with an 8.8-
fold increased risk for CKD and a 3.3-fold increase in ESKD 
(Coca, Singanamala, & Parikh, 2012). It may account for up 
to 20% of the incidence of new dialysis patients (Coca, 2010; 
Coca et al., 2012). However, there are no known effective 
therapies to prevent development of fibrosis after AKI. The 
13th Acute Dialysis Quality Initiative concluded that research 
on the best treatment strategies for targeting progression after 
AKI is a major priority (Basile et al., 2016). Because AKI 
typically occurs in the hospital setting, there is a potential to 
intervene during the acute or early recovery phase to prevent 
the development of fibrosis and CKD.
A large body of evidence supports the conclusion that 
TGF-β plays a critical role in promoting kidney fibrosis, mak-
ing it a prime therapeutic target. However, because TGF-β has 
a broad range of functions in both normal human physiologi-
cal and pathological processes, developing effective therapies 
that target this cytokine has proved very challenging. Global 
inhibition of TGF-β is associated with deleterious effects, 
especially with chronic fibrotic diseases such as CKD that 
require long-term treatment (Nishimura, 2009; Sureshbabu, 
Muhsin, & Choi, 2016). Moreover, global blockade of TGF-β 
may inhibit other actions, such as its anti-inflammatory prop-
erties that promote proper repair (Sureshbabu et al., 2016). 
A more promising approach is to selectively target TGF-β in 
its extracellular microenvironment in the injured tissue and 
prevent the transition from an inactive (latent) to an active 
state (Bouchie & DeFrancesco, 2015). Although TGF-β acti-
vation can occur through various mechanisms, in the context 
of organ injury states that lead to fibrosis it is now well-es-
tablished that locally upregulated integrins are the primary 
mediators of latent TGF-β activation (Henderson et al., 2013; 
Nishimura, 2009; Worthington, Klementowicz, & Travis, 
2011). All five integrins incorporating the αv subunit (αvβ1, 
αvβ3, αvβ5, αvβ6, and αvβ8) have been shown in vitro to 
bind and activate latent TGF-β through the amino acid se-
quence Arg-Gly-Asp (RGD) in the latency-associated peptide 
(Asano, Ihn, et al., 2005; Asano, Yamane, Jinnin, Mimura, & 
Tamaki, 2005; Mu et al., 2002; Munger et al., 1999; Reed et 
al., 2015). Once activated, TGF-β signaling through its own 
receptor induces the expression of many of the same integrin 
subunits (Honda, Yoshida, & Munakata, 2010; Zambruno et 
al., 1995), thereby establishing a local positive amplification 
loop that can perpetuate fibrosis until the loop is disrupted 
by drugs or processes that interfere with TGF-β activation. 
Unlike the global inhibition produced by agents that target al-
ready-activated TGF-β (e.g., fresolimumab and galunisertib), 
integrin antagonism would exploit the body's natural mecha-
nism of locally boosting TGF-β at sites of tissue remodeling. 
Dampening the activity of these induced activated integrins 
is hypothesized to facilitate return to the homeostatic state 
without the systemic side effects that have been observed 
with indiscriminate global anti-TGF-β therapy. Independent 
of their role in TGF-β activation, RGD-binding integrins 
are also critical transducers of biomechanical force allow-
ing cells to respond to matrix stiffness by promoting myo-
fibroblast differentiation, migration, and survival (Fiore et 
al., 2018; Lampi & Reinhart-King, 2018; Santos & Lagares, 
2018). Interference with these signals thus may alter myofi-
broblast numbers and/or functions in an incipient or ongoing 
disease state.
To test the potential therapeutic utility of combined tar-
geting of the subset of RGD-binding integrins implicated in 
pro-fibrotic molecular and cellular processes, we employed 
stable peptidomimetic small-molecule inhibitors of these 
integrins in an established nephrotoxic model of kidney 
fibrosis.
2 |  METHODS
2.1 | Compound synthesis and integrin 
function assays
The RGD peptidomimetic CWHM-12 was synthesized as 
described in detail previously (Henderson et al., 2013). A 
close structural analog of this compound with improved oral 
bioavailability, CWHM-680, was also synthesized at Saint 
Louis University. Potency for the compounds in block-
ing cell attachment mediated by integrins αvβ3, αvβ5, and 
αvβ6 was measured as previously described (Henderson et 
al., 2013). Potency for blocking cell attachment mediated 
by integrins αvβ1, αvβ8, and α8β1 was measured using 
modifications of this method which are briefly summarized 
as follows: To assess CWHM-12 and CWHM-680 effects 
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on cellular αvβ1 function, we varied its concentration in an 
assay measuring binding of HEK-293 cells, which naturally 
express this integrin (Nagarajan et al., 2007), to the surface 
of 96-well plates coated with purified recombinant human 
TGFβ-1 latency-associated peptide (R&D Systems). To as-
sess the effect on cellular αvβ8 function, we performed the 
assay with the same LAP ligand but with HEK-293 cells 
which had been stably transfected to overexpress this in-
tegrin. To assess the effect on cellular α8β1 function, we 
performed the assay using HEK-293 cells, which had been 
stably transfected to overexpress this integrin and used pu-
rified recombinant mouse nephronectin as the immobilized 
ligand (R&D Systems). To assess the effect on cellular 
α5β1 function, we performed the assay using K562 cells, 
which naturally express this integrin and used purified 
human plasma fibronectin (Calbiochem/EMD Biosciences) 
as the immobilized ligand. For all assays except α8β1, the 
optimal ligand concentration was defined as that providing 
maximum inhibition of the relevant cell binding by known 
specific function-neutralizing antibodies while retaining 
strong binding in the presence of isotype-matched nega-
tive control antibodies. Because no validated α8-specific 
neutralizing antibodies are commercially available, optimi-
zation of ligand coating was performed by comparison of 
attachment of the α8β1-overexpressing cells to the parental 
nontransfected cells.
2.2 | Kidney injury model
Alzet osmotic minipumps (Cupertino, CA) were implanted 
subcutaneously in 8- to 10-week-old wild-type male ICR 
outbred mice (Envigo) one day prior to induction of kidney 
injury to deliver vehicle (DMSO/H2O 1:1) or CWHM-12 
at a dose of 100  mg/kg per day. A single 5  mg/kg dose 
of aristolochic acid I sodium salt (Sigma-Aldrich, A9451) 
in PBS was administered intraperitoneally to induce kid-
ney injury, and mice were monitored daily for 27  days 
thereafter. Control (uninjured) mice were injected with an 
equal volume of PBS. Blood was obtained by maxillary 
vein puncture on days 0, 5 (peak injury), and 28 (study 
endpoint). For testing CWHM-680, oral gavage (100 mg/
kg per day) was started one day prior to injection of aris-
tolochic acid I sodium salt and continued once daily until 
the study endpoint. Blood was obtained at days 0, 7, and 23 
(study endpoint). Animals that did not survive until the end 
of the study were not included in serum creatinine analy-
sis. Serum creatinine was measured by liquid chromatogra-
phy–mass spectrometry (LC–MS/MS) at the University of 
Alabama O’Brien Center Bioanalytical Core. CWHM-12 
and CWHM-680 concentrations were measured in plasma 
samples by liquid chromatography–tandem mass spec-
trometry (LC/MS/MS) using compound spiked into control 
plasma as a standard. All experiments were performed 
under protocols approved by the Institutional Animal Care 
and Use Committee at St. Louis University.
2.3 | Tissue preparation, histology, and 
immunofluorescence
Harvested kidneys were bisected and harvested for RNA 
and protein, and fixed in 4% PFA for antibody staining and 
histological staining with Sirius red or Masson's trichrome. 
Paraffin sections (4  µm) were stained with Sirius red or 
Masson trichrome and imaged with polarized light and 
bright-field illumination. For immunofluorescence, 7-μm 
frozen sections were washed with ice-cold 100% methanol, 
boiled in 10 mM citric acid (pH 6) for 20 min, and incu-
bated with primary antibodies against αSMA (Millipore), 
PDGFR-β (gift from B. Stallcup), or with  biotin-LTL 
(Vector Laboratories). Reactivity was detected using flu-
orescently labeled secondary antibodies. Sections were 
counterstained with DAPI (Sigma-Aldrich), mounted in 
Mowiol 4–88 (Poly Sciences), and digital images acquired 
using a Leica DM5000B epifluorescence microscope and 
Leica DFC365FX camera. To quantify percent area stained 
for Sirius red, PDGFR-β, and α-SMA, we analyzed im-
ages from each of at least 4 biological replicates by batch 
processing using a macro created in Image J. Images were 
converted to 8-bit grayscale, the threshold adjusted, and 
percent area measured. To quantify intact proximal tubules 
with brush borders, LTL-positive tubules were counted by 
an observer blinded to the experimental conditions using 
Image J.
2.4 | Quantitative PCR
RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). 
cDNA was prepared using the High-Capacity RNA-to-
cDNA Kit (Applied Biosystems). qRT-PCR was performed 
using a Quant Studio 3 (Applied Biosystems) Thermocycler 
and SYBR Green PCR Master Mix (Life Technologies). 
The following primers were used for qRT-PCR: Col1a1 
5′-ATGTTCAGCTTTGTGGACCTCC-3′ and 5′-CAAGC 
ATACCTCGGGTTTCC-3′, Col3a1 5′-GCGAGCGGCTG 
AGTTTTATG-3′ and 5′-TAGGACTGACCAAGGTGGCT- 
3′, Acta2 5′-ATCTGGCACCACTCTTTCTATAACG-3′ and 
5′-CAGTTGTACGTCCAGAGGCA-3′, Tgfb1 5′-CAACAA 
TTCCTGGCGTTACC-3′ and 5′-AGCCCTGTATTCCGT 
CTCCT-3′, Tgfb2 5′-CAAAACCCCAAAGCCAGAGTG-3′ 
and 5′-TCACGTCGAAGGAGAGCCAT-3′, Tgfb3 5′-GCA 
CTTTACAACAGCACCCG-3′ and 5′-ACTCTGCCCGGAA 
CAGATTG- 3′, Fn1 5′-GCTTTAAGCTCACATGCCAGT-3′ 
and 5′-GAGGCATGTGCAGCTCATC-3′, Foxd1 
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5′-GTTTAGCTCAGAGGGTCCATCTAT-3′ and 5′-AGTGC 
CAAGACAGAGCGACT-3′, Pdgrfb 5′-AACTGTCACCC 
ACACCCTTG-3′ and 5′-ACCACCACTTTGAAGGGCAA- 
3′, Mmp2 5′-GATAACCTGGATGCCGTCGT-3′ and 5′- 
TGGTGTGCAGCGATGAAGAT-3′, Ctgf 5′-AGAGTGGAG 
CGCCTGTTCTA-3′ and 5′-GGCTTGGCGATTTTAGGTG 
TC-3′, Shroom3 5′-AATTTGGGGAGACACAGCCT-3′ and 
5′-GCTCCGCCTCAGATAAGCAT-3′, Itga5 5′-ATCCAGT 
GCACCACCATTCA-3′ and 5′-TCCGAACCACTGCAAGG 
AC-3′, and Itgb5 5′-CACCCAAAATGTGCCTGGTG-3′ 
and 5′-AGAGGTAGGTTCCGGAGGAC-3′. Real-time 
reactions were performed in triplicate, and relative expres-
sion was calculated using the delta CT method and normal-
ized to Gapdh 5′-AGGTCGGTGTGAACGGATTTG-3′ and 
5′-TGTAGACCATGTAGTTGAGGTCA-3′ or Hprt1 5′-TCA 
GTCAACGGGGGACATAAA-3′ and 5′-GGGGCTGTACTG 
CTTAACCAG-3′ control transcripts (Kiefer, Robbins, & 
Rauchman, 2012).
2.5 | RNA sequencing
Total RNA was isolated from four kidneys from each of the 
three study groups using the RNeasy Plus Mini Kit (Qiagen). 
The groups were as follows: (a) aristolochic acid plus vehi-
cle, (b) aristolochic acid plus CWHM-12, and (c) PBS plus 
vehicle. After ribosomal depletion, we constructed barcoded 
sequencing libraries using the Ion Total RNA-seq v2 kits 
(Life Technologies) according to the manufacturer's instruc-
tions. Sequencing was performed on an Ion Torrent Proton 
with mean read lengths of 85–110 nucleotides, and reads 
were aligned to the mouse mm10 genome using the TMAP 
aligner map4 algorithm. Soft clipping at both 5′ and 3′ ends 
of the reads was permitted during alignment to accommodate 
spliced reads, with a minimum seed length of 20 nucleotides. 
Genome-wide strand-specific nucleotide coverages were 
calculated from the aligned bam files for each sample using 
the “genomecoveragebed” program in BEDTools (Quinlan 
& Hall, 2010), and the nucleotide coverage for all nonre-
dundant exons for each gene was summed using custom R 
scripts (http://www.Rproj ect.org). Normalization factors 
were calculated by averaging the total exon coverage for all 
replicates and dividing this average by the total exon cover-
age for each individual sample. The total coverage for each 
gene in each replicate was then multiplied by these factors 
after adding an offset of 1 to each gene to preclude division 
by 0 in subsequent calculations. The averages and p values 
of the coverage values for all genes in the individual groups 
were calculated using Microsoft Excel, using a two-tailed 
t-test. The expression values for each gene are the normal-
ized strand-specific total nucleotide coverage for each gene. 
The complete data set can be accessed at https ://figsh are.
com/s/54c7f 78b45 23873 e9b00 .
2.6 | Western blotting
Protein lysates were made by homogenizing kidney tissue in 
cold 50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 
and 200 mM sucrose with protease inhibitors using a Tissue 
Tearor. Protein lysates were run on SDS-PAGE gels and pro-
teins detected using Collagen 1 (Proteintech, cat# 14695-1-
AP, 1:3,000) and HDAC2 (Abcam, cat# ab32117, 1:3,000) 
primary antibodies and peroxidase-labeled goat anti-rabbit 
secondary antibody (Sigma-Aldrich, cat# A0545, 1:10,000). 
Signal was developed with SuperSignal West Dura (Thermo 
Fisher). Collagen 1 densitometry was performed using Image 
J and normalized to HDAC2.
2.7 | Statistical analysis
Data are presented as the mean ± SEM. Statistical analysis was 
performed using a one-tailed unpaired Student's t-test or ANOVA 
followed by multiple comparisons analysis with Tukey's correc-
tion (GraphPad Prism). Statistical analysis for each experiment 
is noted in the figure legend. We considered differences with a p 
value of .05 or less to be statistically significant.
3 |  RESULTS
3.1 | CWHM-12 inhibits cell–ligand 
interactions mediated by RGD integrins
The small-molecule RGD peptidomimetic compound 
CWHM-12 has been shown previously to inhibit cell–ligand 
interactions mediated by αvβ3, αvβ5, and αvβ6, and the in-
teractions of biochemically purified integrins αvβ1 and αvβ8 
with their respective ligands (Henderson et al., 2013). We 
have now determined the potency of this compound against 
these and additional RGD-binding integrins entirely using 
cell-based assays (Table 1). These results show particularly 
strong potency (<1 nM) for αvβ1, αvβ3, and αvβ6, with var-
ying lesser activities for the other tested RGD-binding inte-
grins. As previously reported, CWHM-12 has no significant 
activity (>5 μ M) against integrin αIIbβ3, which is essential 
for platelet aggregation, nor does it affect ligand binding by 
non-RGD-binding integrins (Henderson et al., 2013).
3.2 | CWHM-12 ameliorates kidney 
function and fibrosis in a model of 
nephrotoxic injury
We examined the effect of CWHM-12 treatment on kidney fibro-
sis in a nephrotoxic model of acute kidney injury. Mice received 
an intraperitoneal injection of aristolochic acid (AA, 5 mg/kg 
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body weight) to induce injury and were monitored for 27 days. 
CWHM-12 (100 mg/kg body weight) or vehicle control was de-
livered subcutaneously by Alzet minipump beginning one day 
prior to induction of kidney injury (Figure 1a). Determination 
of compound levels from blood samples collected on various 
days showed the mean steady plasma drug concentration was 
approximately 5  µg/ml (Table S1 https ://figsh are.com/s/54c7f 
78b45 23873 e9b00 ), similar to that measured in previous stud-
ies in which this dosing regimen was used to evaluate efficacy 
in other models (Henderson et al., 2013; Ulmasov et al., 2016). 
At day 5 after AA injection, serum creatinine was significantly 
increased in both control and CWHM-12-treated injured ani-
mals (Figure 1b), consistent with previous studies showing acute 
injury due to AA (Hirsch et al., 2015; Novitskaya et al., 2014; 
Yang, Besschetnova, Brooks, Shah, & Bonventre, 2010). At day 
27, serum creatinine was reduced from its peak value at day 5 
in CWHM-12-treated animals but not in vehicle-treated injured 
animals (0.15 mg/dl ± 0.027 vs. 0.32 mg/dl ± 0.048, p = .0334). 
We conclude that CWHM-12 treatment protects kidney function 
in a model of nephrotoxic injury.
Aristolochic acid administration is a recognized cause 
of postacute kidney injury fibrosis in mice and humans 
(Novitskaya et al., 2014; Yang et al., 2010). In rodent mod-
els, fibrosis was apparent within 14  days of AA admin-
istration and was progressively worse at day 28. We next 
examined whether the improvement in renal function at 
27 days in CWHM-12-treated animals correlated with a re-
duction in kidney fibrosis. To determine drug effect on kid-
ney fibrosis, we measured pro-fibrotic gene expression and 
performed staining on kidneys to assess interstitial collagen 
deposition. Collagen 1 (Col1a1) mRNA expression was in-
creased 32-fold by qRT-PCR in AA-injected animals treated 
with vehicle compared with uninjured animals. In contrast, 
in injured animals treated with CWHM-12, Col1a1 expres-
sion was increased just 9-fold. Collagen 1 protein expression 
was similarly reduced threefold as determined by Western 
blot in CWHM-12 compared with vehicle treatment. Thus, 
CWHM-12 significantly attenuated upregulation of Col1a1 
(Figure 2a and b), a major component of ECM deposition 
in organ fibrosis, at the mRNA and protein level. Sirius red 
T A B L E  1  Potency of test compounds in inhibiting integrin-mediated cell attachment to ligandsa
  αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α8β1
CWHM−12 0.29 ± 0.14 0.47 ± 0.45 47 ± 26 0.31 ± 0.14 5.8 ± 2.3 8.0 ± 3.9 35 ± 16
CWHM−680 1.24 ± 0.12 1.18 ± 0.74 4.5 ± 2.2 0.39 ± 0.17 18.6 ± 5.0 100 ± 37 424 ± 295
aValues represent the mean IC50 (nM) and standard deviation determined from at least 3 independent assays. 
F I G U R E  1  (a) Schematic of study 
design. Osmotic minipumps were inserted 
one day prior (day −1) to administration 
of aristolochic acid (AA, day 0) to induce 
kidney injury. Animals were randomized to 
receive CWHM-12 at 100 mg kg−1 day−1 
or vehicle for 27 days after AA. (b) Serum 
creatinine (sCr mg/dl) in injured (AA) 
and uninjured (PBS) animals that received 
vehicle or CWHM-12. sCr was significantly 
decreased at day 27 in AA-treated animals 
that received active drug (CWHM-12) 
compared with vehicle. In uninjured (PBS) 
control animals, sCr was not affected 
by CWHM-12. PBS + vehicle, n = 5; 
PBS + CWHM-12, n = 5; AA + vehicle, 
n = 9; AA + CWHM-12, n = 7. In (b), 
data were analyzed by two-way ANOVA 
followed by multiple-group comparison 
analysis with Tukey's correction, *p < .05
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staining to assess scar collagen deposition in injured kidneys 
revealed a 68% (p <  .0001) reduction in the percentage of 
area stained in CWHM-12-treated animals compared with 
vehicle-treated (Figure 2c and d). Masson trichrome stain-
ing showed reduced collagen deposition in drug versus ve-
hicle-treated animals (Figure 2e). The reduction in fibrosis 
and improved kidney function in CWHM-12-treated ani-
mals suggested that repair or preservation of injured tubules 
would be enhanced by drug treatment. We quantitated the 
number of proximal tubules with intact brush borders based 
on LTL staining (Figure 2f). The number of intact proximal 
tubules was significantly greater in CWHM-12-treated kid-
neys at 27 days after AA induced injury compared with ve-
hicle-treated animals (57.1 ± 1.7 vs. 40.9 ± 1.6, n = 5 for 
each group, p < .0001). These results demonstrated that in-
hibition of RGD integrins preserved intact proximal tubules, 
and ameliorated kidney fibrosis and renal dysfunction in a 
model of nephrotoxic kidney injury. Because sCr was not 
significantly different at day 5, the protective effect at day 
27 cannot be attributed to a difference in the severity of the 
initial injury.
To comprehensively analyze the effect of CWHM-12 on 
pro-fibrotic gene expression, we compared mRNA levels 
in kidneys of AA-injured animals treated with vehicle and 
CWHM-12 by RNA sequencing (RNA-seq). We also ana-
lyzed the mRNA expression in vehicle-treated uninjured 
animals. Injury-induced expression of multiple pro-fibrotic 
genes was significantly reduced in injured mice treated with 
CWHM-12 compared with vehicle (p < .05, n = 3 biologi-
cal replicates). This includes components of the extracellular 
matrix (ECM) (collagens, fibronectin, matrix metallopep-
tidases) and pro-fibrotic cytokines, TGF-β1-3, and CTGF 
(Figure 3a and Table 2). Shroom3 is a TGFβ-1 target gene 
that promotes kidney fibrosis (Menon et al., 2015). In hu-
mans, an intronic SNP that conferred increased expression of 
this gene is associated with CKD in GWAS and with fibrosis 
in kidney allografts (Kottgen et al., 2009, 2010; Menon et al., 
2015). Injury-induced expression of Shroom3 was attenuated 
by CWHM-12 in injured kidneys (Figure 3a and Table 2). We 
performed qRT-PCR to validate the gene expression changes 
determined by RNA-seq for 12 pro-fibrotic genes. Relative 
expression changes were in agreement with the RNA-seq 
(Figure 3a and b).
TGF-β is a central mediator of organ fibrosis in multiple 
tissues, including kidney. The ability of CWHM-12 to inhibit 
the activation of latent TGF-β in the ECM is predicted to be a 
major mechanism by which this compound ameliorated kid-
ney fibrosis in our model. Consistent with this observation, 
pathway analysis of the RNA-seq data showed that genes 
responding to TGF-β signaling were significantly reduced 
(Figure 5, p = 10–7). However, in addition to promoting for-
mation of myofibroblasts and pro-fibrotic gene expression, 
TGF-β also induces the expression of RGD integrin subunits 
and TGF-β itself, thereby creating a self-reinforcing loop 
(Honda & Munakata, 2010; Zambruno et al., 1995). Thus, 
treatment with CWHM-12 would also be predicted to reduce 
RGD integrin and TGF-β expression. As shown in Figure 3a, 
Tgfb1-3 mRNA expression was induced with injury as ex-
pected, but this was blunted in CWHM-12-treated mice. The 
RNA-seq data also revealed that expression of the subunits 
that form RGD-binding integrins increased in expression 
with injury, whereas the expression of this group was reduced 
by CWHM-12 (Figure 3b). Thus, treatment with CWHM-12 
disrupted the amplification of pro-fibrotic TGF-β signaling 
mediated by the autoregulatory loop with RGD integrins.
Myofibroblasts are the principal source of extracellular 
matrix deposition in kidney fibrosis. In AA-injured kidneys, 
we found significant upregulation of several specific mark-
ers of activated myofibroblasts in the injured kidney that 
reflects their origin from perivascular mesenchymal cells 
(Grgic et al., 2014). Compared with vehicle, CWHM-12 
treatment markedly reduced Gli1 (20.4- vs. 9.2-fold), Pdgfra 
(5.0- vs. 3.7-fold), Pdgfrb (6.8- vs. 3.0-fold), Foxd1 (9.6- vs. 
3.3-fold), and Crlf1 (37.6- vs. 3.9-fold) expression (Figure 
4c and Table 3). We also examined myofibroblast formation 
by immunostaining kidneys with antibodies to αSMA and 
F I G U R E  2  (a) Collagen 1 (Col1a1) mRNA expression was determined by real-time PCR in injured and uninjured control animals treated 
with CWHM-12 or vehicle. Relative to vehicle-treated animals, the induction of Col1a1 mRNA expression was attenuated in AA-injured animals 
treated with CWHM-12 (32-fold vs. 9-fold, compared with controls). AA + vehicle n = 9, AA + CWHM-12, n = 7. (b) Collagen 1 protein was 
detected by Western blot in animals treated with CWHM-12 or vehicle. Quantitation by densitometry revealed a threefold reduction in Collagen 1 
(0.719 ± 0.13 vs. 2.14 ± 0.39 arbitrary units, p = .00345, n = 6 for each group) with CWHM-12 treatment. (c) Quantitation of collagen deposition 
by analysis of percent area kidney sections stained by Sirius red. Relative to vehicle-treated animals, the percent area stained by Sirius red was 
reduced by 68% in AA-injured animals that were treated with CWHM-12. n = 5 for each AA group, with at least 40 images analyzed for each 
group, ****p <.0001. (d) Bright-field and polarized light images are shown for Sirius red staining of kidney tissue. Quantitation was performed 
using polarized light, scale bar = 25µm. (e) Masson trichrome staining revealed a reduction in collagen staining in CWHM-12 compared with 
vehicle-treated animals. One low power image (scale bar = 200µm) shown for each group and 3 different images from 3 different kidneys for each 
group shown in higher power (scale bar = 100 µm). (f) LTL staining showed significantly increased proximal tubules with intact brush borders in 
CWHM-12-treated animals compared with vehicle-treated. At least 8 images from each biological replicate were counted from each group, n = 5 
for each group, ****p < .0001, scale bar = 50µm. For a and c, data were analyzed by ANOVA followed by multiple-group comparison's analysis 
with Tukey's correction. For b and f, data were analyzed by unpaired t-test
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PDGFR-β. We found that the percentage of area of expres-
sion for these proteins was reduced by 45% (p < 10–6) for 
αSMA and by 44% for PDGFR-β (p  =  .008) by CWHM-
12 treatment compared with vehicle-treated animals (Figure 
4a and b). We also compared our RNA-seq data to that of 
Grgic et al. (2014) who performed transcriptional profiling 
of isolated myofibroblasts after unilateral ureteral obstruc-
tion (UUO) to identify genes induced in response to injury. 
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We found that novel biomarkers of activated myofibroblasts 
identified by Grgic et al. were also significantly upregulated 
in our AA injury model (Figure 4c). Importantly, treatment 
with CWHM-12 abrogated the induction of these genes, in-
dicating that inhibition of RGD integrins prevented expan-
sion or activation of myofibroblasts.
3.3 | Multiple pro-fibrotic pathways are 
attenuated and repair processes are enhanced 
by CWHM-12
The RNA-seq data also revealed that biomarkers impli-
cated in kidney fibrosis and dysfunction were ameliorated 
F I G U R E  3  (a) Gene expression determined by RNA-seq in injured (AA) animals exposed to vehicle or CWHM-12. Expression of pro-
fibrotic cytokines Tgfb1, Tgfb2, Tgfb3, and Ctgf, genes encoding extracellular matrix proteins Col1a1, Col3a1, Mmp2, and Fn1, and the TGF-β 
target gene Shroom3 was reduced in CWHM-12-treated injured kidneys compared with vehicle-treated. (p values are shown in Table 2). The 
expression level of pro-fibrotic genes by qRT-PCR was very similar to the RNA-seq. (b) Expression of genes encoding RGD integrins was induced 
by injury. CWHM-12 treatment significantly reduced the expression of all the RGD integrin genes, but only Itgb5 reached statistical significance. 
RNA-seq was performed on 4 biological replicates for each group. Itga5 and Itgb5 expression changes by qRT-PCR were in agreement with RNA-
seq. For qRT-PCR in a and b, data were analyzed by unpaired t-test. All qRT-PCR comparisons reached significance except for Acta2
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by CWHM-12 treatment. NGAL (Lcn2), a well-established 
biomarker of acute and chronic kidney injury (Kiryluk et al., 
2018), was induced 144-fold in AA-injured/vehicle-treated 
relative to uninjured. In CWHM-12-treated/AA-injured 
kidneys, NGAL expression decreased by 50% compared 
with vehicle-treated injured mice. Reduced EGF expression 
has been associated with a higher percent area of interstitial 
fibrosis in human kidney tissue (Beckerman et al., 2017). 
In AA-injured mice, Egf expression was reduced by 51% 
compared with uninjured mice, whereas Egf expression was 
increased twofold with CWHM-12 treatment of injured ani-
mals. Multiple keratin (Krt) genes were recently identified 
as biomarkers of post-AKI fibrosis (Cippà et al., 2018). We 
found that eight keratin genes (Krt 7, 8, 15, 18–20, 23, and 
80) were upregulated with injury; in each case, the degree of 
upregulation was significantly reduced by ~15%–50% with 
CWHM-12 administration.
Sox9 is a transcriptional regulator that has a role in renal 
epithelial cell repair after acute injury; its expression was 
shown to be persistently elevated in the transition from AKI 
to CKD and fibrosis (Kang et al., 2016; Kumar et al., 2015; 
Li et al., 1864). Induction of Sox9 (45-fold) was decreased 
by 57% by CWHM-12. Sox9 has been linked to proliferat-
ing tubular epithelia after injury. In addition to Sox9, other 
genes associated with proliferation (Fosl2, Myc, Ccnb1, 
F I G U R E  4  (a–b) Quantitation of 
percent area immunostained by PDGFR-β 
and α-SMA. Relative to vehicle-treated 
animals, the percent area stained for 
PDGFR-β (p = .008) and α-SMA 
(p = 9.8 × 10−7) was reduced by 44% 
and 45%, respectively, in AA animals 
that were treated with CWHM-12. For 
PDGFR-β, n = 5 biological replicates 
with at least 20 images analyzed for 
each group; for α-SMA, n = 5 biological 
replicates with at least 40 images analyzed 
for each group, scale bar = 100 µm. (c) 
Myofibroblast gene expression by RNA-seq. 
Expression of multiple markers of activated 
myofibroblasts was induced by AA-injured 
animals. CWHM-12 significantly attenuated 
expression of these genes, with Pdgfrb, 
Foxd1, Gli1, and Crfl1 reaching statistical 
significance at p < .05. RNA-seq was 
performed on 4 biological replicates for 
each group. p values are shown in Table 3. 
For a and b, data were analyzed by unpaired 
t-test
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T A B L E  2  Fold change of profibrotic genes by RNA-seq
Gene
AA +  
Vehicle
AA +  
CWHM−12
AA +  
CWHM−12/
AA + Vehicle p value
Col1a1 42.1 10.4 0.2480 .0013
Col3a1 28.0 10.0 0.3560 .0118
Mmp2 24.6 9.9 0.4013 .0116
Fn1 12.6 6.6 0.5243 .0949
Tgfb3 8.3 4.9 0.5937 .0738
Tgfb1 7.4 4.2 0.5715 .1163
Ctgf 6.4 3.5 0.5510 .1690
Tgfb2 4.9 4.1 0.8306 .6904
Shroom3 3.9 2.2 0.5633 .0871
Acta2 3.7 3.2 0.8473 .3541
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Cdk1) induced by injury displayed attenuated expression 
with CWHM-12 compared with vehicle treatment. The cell 
cycle regulators Ccnb1 and Cdk1 were markedly upregu-
lated in injured kidneys exposed to vehicle, 23-fold and 12-
fold, respectively. CWHM-12 treatment reduced expression 
to levels that were only 1.4-fold and 1.9-fold higher than in 
vehicle-treated injured kidneys, suggesting that proliferation 
of tubular epithelia, myofibroblasts, or both was reduced by 
CWHM-12. This is consistent with an attenuation of the in-
jury response.
Pathway analysis of the RNA-seq data revealed that 
CWHM-12 affected biological processes that are consis-
tent with reduced injury and enhanced repair. Cell adhesion 
and extracellular matrix organization are related pathways 
that were significantly upregulated with kidney injury and 
fibrosis in our data, and this is in agreement with (Cippà 
et al., 2018). However, when comparing drug and vehi-
cle treatment we found that expression of genes in these 
same pathways was significantly attenuated by CWHM-12 
(Figure 5). Other well-established pro-fibrotic pathways 
were downregulated with CWHM-12 treatment, includ-
ing WNT and TGF-β signaling (Figure 5). Mitochondrial 
dysfunction plays an important role in the pathogenesis 
of kidney injury via its critical role in cellular energet-
ics and regulation of apoptosis. Compared with vehicle, 
CWHM-12 treatment in animals exposed to AA showed 
gene expression changes that reflected improved oxidative 
phosphorylation and a reduction in the apoptotic pathway. 
Overall, the RNA-seq data supported the conclusion that 
multiple deleterious pro-fibrotic pathways were attenuated 
and processes indicative of adaptive repair or recovery 
were enhanced by treatment with this RGD integrin antag-
onist in nephrotoxic injury.
3.4 | An orally dosed RGD peptidomimetic 
compound ameliorates kidney fibrosis
To enhance the potential for translation to the clinic, we 
evaluated whether CWHM-680, an analog of CWHM-12 
with significant oral bioavailability (F = 45% in mouse), 
could also reduce kidney fibrosis. As shown in Table 1, 
CWHM-680 also potently inhibits the alpha v subfamily 
F I G U R E  5  Gene ontology analysis 
of differentially expressed genes in 
injured animals treated with drug versus 
vehicle. Bar graph indicating p values for 
biological processes and pathways that were 
downregulated or upregulated by CWHM-
12 treatment compared with vehicle control 
in injured animals. Several pathways that 
promote fibrosis, such as TGF-β and Wnt, 
were reduced by CWHM-12 treatment, 
whereas pathways or processes associated 
with repair were upregulated
0 2 4 6 8 10 12 14 16
Regulation of cell communication
Extracellular matrix organization
Cell adhesion
Wnt signaling pathway
Cell–cell signaling by wnt
Cellular response to TGF-b stimulus
Wound healing
Ribosome
Collagen metabolic process
Regulation of apoptotic process
Heme binding
TGF-b receptor signaling pathway
DNA repair
Oxidation–reduction process
Fatty acid metabolic process
-Log10 P-value
RNA-seq gene ontology
Upregulated
Downregulated
T A B L E  3  Fold change of genes expressed in myofibroblasts by 
RNA-seq
Gene
AA +  
Vehicle
AA +  
CWHM−12
AA + 
CWHM−12/
AA + Vehicle p value
Rgs16 55.80 26.19 0.4692 .16075
Crlf1 37.57 3.88 0.1032 .00004
Aldh1a2 32.44 21.06 0.6492 .12267
Gli3 24.87 15.02 0.6039 .23568
Gli1 20.44 9.17 0.4486 .00333
Foxd1 9.55 3.27 0.3427 .00829
Nes 8.77 3.91 0.4461 .05825
Thbs4 8.72 3.97 0.4558 .13873
Gda 8.17 5.15 0.6302 .20202
Thbs2 7.78 4.36 0.5603 .20064
Pdgfrb 6.79 2.98 0.4393 .03738
Col5a3 5.81 3.25 0.5587 .23788
Fbln2 5.78 3.04 0.5262 .07217
Pdgfra 5.02 3.66 0.7298 .26646
Gli2 0.87 0.78 0.8986 .81055
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of integrins, though it is comparatively less potent against 
α5β1. We administered vehicle or CWHM-680 (100  mg/
kg body weight) once daily by oral gavage beginning two 
days prior to injury by administration of AA (Figure 6a). 
Average total compound concentrations measured from 
blood samples collected just prior to administration of the 
next scheduled dose on days 1, 7, and 23 were 0.385, 0.464, 
and 2.279  µg/ml, respectively (Table S2 https ://figsh are.
com/s/54c7f 78b45 23873 e9b00 ), in injured animals. These 
trough levels of CWHM-680 were approximately 2–14 
times lower than the steady-state concentration measured 
in mice continuously infused with CWHM-12. Although 
we did not find a reduction in sCr at the study endpoint 
(Figure 6b), several independent measures indicated that 
CWHM-680-treated animals developed less kidney fibro-
sis. Col1a1 mRNA expression was reduced 3-fold, and 
fibronectin was reduced by 22% with drug treatment com-
pared with control animals (Figure 6c). Consistent with the 
reduction in scar collagen expression, we found that the 
percentage area staining for Sirius red was reduced by 52% 
(p = .0006, n = 4 for each group, Figure 6d). Pdgfrb mRNA 
expression was reduced by 33% and Acta2 was reduced by 
28% with CWHM-680 treatment, indicating that the drug 
limited myofibroblast formation after injury (Figure 6c). 
However, in contrast to CWHM-12, CWHM-680 did not 
reduce the percent area of αSMA or Pdgfr-β staining or 
Tgfb expression (Figure 6c and e–f), suggesting that the 
CWHM-680 oral treatment regimen may have been less 
effective overall than the CWHM-12 infusion method for 
several possible reasons (see Discussion).
4 |  DISCUSSION
TGF-β signaling is a central mediator of fibrosis in multiple tis-
sues. Consequently, targeting its activity has been the goal of 
many drug strategies. However, global targeting of TGF-β in 
the clinic has been unsuccessful due to serious adverse effects 
stemming from its diverse roles in normal physiology. A more 
promising approach is to target integrin activators of TGF-β 
which are locally upregulated at sites where fibrosis is being 
stimulated. All five members of the alpha v integrin family 
(αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8) have been shown to be ex-
pressed at sites of injury either on damaged epithelial cells or on 
activated myofibroblasts. They all bind to the arginine–glycine–
aspartic acid (RGD) motif of the latency-associated peptide 
(LAP) and are capable of releasing biologically active TGF-β 
that triggers a pro-fibrotic signaling program (Henderson et al., 
2013; Nishimura, 2009; Worthington et al., 2011).
Here, we report that blocking activation of TGF-β with 
small-molecule peptidomimetic inhibitor of a subset of 
RGD integrins reduced pro-fibrotic gene expression, re-
duced kidney fibrosis, and ameliorated renal function in 
a model of nephrotoxicity. The steady-state drug levels of 
CWHM-12 we measured with continuous administration 
by minipump were very similar to those found to reduce 
fibrosis after pancreatic injury and likely represent a max-
imally effective dose (Ulmasov et al., 2016). In addition to 
ameliorating kidney fibrosis and renal impairment, it is sig-
nificant that we did not observe obvious deleterious effects 
in CWHM-12-treated animals. This is consistent with data 
from clinical studies for cancer indications in which RGD 
integrin inhibitors with varying target selectivity profiles 
were found to be generally well-tolerated and safe (Cirkel 
et al., 2016; Hariharan et al., 2007; O'Day et al., 2011). 
However, more detailed toxicology studies will be needed 
to ensure the safety of such compounds for treatment of 
kidney diseases. In addition to therapeutic efficacy, the 
route of administration is an important consideration for 
translating a therapy to the clinic for kidney fibrosis; an 
oral agent is preferred because long-term treatment is re-
quired. We therefore tested an analog of CWHM-12 with 
improved oral bioavailability in our nephrotoxicity model. 
CWHM-680 was also effective in ameliorating kidney fi-
brosis, but it did not reduce sCr at the study endpoint of 
23 days. The differing pharmacokinetic and pharmacody-
namic profiles for the two compounds, one delivered by 
continuous infusion and the other with daily oral gavage, 
likely account for the overlapping but distinct endpoint 
outcomes of the two drugs. Moreover, we cannot exclude 
the possibility that their different potency for inhibition of 
α5β1 integrin may be a contributing factor (Table 1), as 
discussed below. While further studies are needed to op-
timize dosing of CWHM-680 and test longer study end-
points, our data indicate that this oral agent was effective 
in ameliorating fibrosis.
Alpha v (αv) integrins are ubiquitously expressed in the 
adult kidney (Pozzi & Zent, 2013), so there is potential for 
functional redundancy when these receptors are activated 
during repair processes. The fact that most RGD integrins 
were upregulated with injury in our study (Figure 3b) fur-
ther underscores the potential functional redundancy, thereby 
supporting the utility of an antagonist of multiple RGD inte-
grins. In support of this idea, different αvβ integrin heterod-
imers have been implicated in kidney fibrosis. αvβ6 integrin 
is expressed on renal tubular epithelia and is upregulated 
in response to injury (Breuss et al., 1995; Ma et al., 2003). 
Genetic deletion of the integrin β6 subunit confers signifi-
cant protection from development of fibrosis and activation 
of TGF-β signaling in unilateral ureteral obstruction (Ma et 
al., 2003). In a model of nephrotoxic injury due to adenine, 
a small model inhibitor of αvβ1 ameliorated kidney dysfunc-
tion and fibrosis (Chang et al., 2017). Kidney myofibroblasts 
express several αv integrins (αvβ1, αvβ3, αvβ5) (Chang et 
al., 2017). Cell-selective αv deletion from the myofibroblast 
lineage was protective against fibrosis in several organ injury 
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models including kidney (Henderson et al., 2013). Our stud-
ies showed a significant reduction in the percent area stained 
for SMA and PDGFR-β, protein markers of myofibroblasts, 
in CWHM-12-treated animals. We also found that myofibro-
blast gene expression was broadly attenuated by this com-
pound. Together, these findings indicate that effects of RGD 
integrin antagonism on formation or activity of myofibro-
blasts are important for its protection against kidney fibrosis. 
There are some reports showing that loss of specific integrins 
may predispose mice to kidney fibrosis (Pozzi & Zent, 2013). 
For example, mice lacking α8 (i.e., α8β1) showed increased 
fibrosis after UUO (Hartner et al., 2012). Our data using a 
cell-based assay of α8β1-mediated nephronectin binding sug-
gest CWHM-12 may be only a weak inhibitor of this integrin. 
Since the compound has much stronger activity against other 
pro-fibrotic integrins, this may have been sufficient to coun-
teract this potentially opposing effect.
Beckerman et al. recently showed that global gene ex-
pression was a very sensitive indicator of fibrosis in human 
kidneys and this in turn was a strong determinant of renal 
function (Beckerman et al., 2017). Similarly, analysis of 
our RNA-seq data revealed that RGD integrin blockade in-
fluenced many pathways linked to fibrosis and improved 
renal function in a model of nephrotoxicity. Consistent with 
the important role of RGD integrins in activating latent 
TGF-β, we found that CWHM-12 inhibited TGF-β signal-
ing and its pro-fibrotic gene targets. However, our data also 
revealed significant effects on other biological processes 
that influence the development of kidney fibrosis and CKD 
progression (Figure 5). Reduced levels of intrarenal EGF 
mRNA and urinary EGF protein strongly correlated with 
interstitial fibrosis, estimated GFR, and rate of decline in 
kidney function in three independent patient cohorts (Ju et 
al., 2015). Consistent with this finding, Egf mRNA expres-
sion was reduced in our nephrotoxicity model. However, 
importantly, reduced expression was abrogated by CWHM-
12 treatment. In addition to being a biomarker for CKD, 
several studies support a functional role for EGF signaling 
in kidney fibrosis (Kok, Falke, Goldschmeding, & Nguyen, 
2014; Liu et al., 2012; Lyu et al., 2018). A recent study iden-
tified a metabolic switch from oxidative phosphorylation 
to glycolysis associated with tubulointerstitial fibrosis and 
progressive CKD in human kidneys (Lemos et al., 2018). 
These data indicated that this process was driven by innate 
immune signals and Myc-dependent gene transcription. 
Our results revealed that CWHM-12 reduced gene expres-
sion associated with innate immunity and partially restored 
expression of genes associated with oxidative phosphor-
ylation in injured kidneys. Moreover, CWHM-12 also re-
duced Myc expression by 35%, suggesting its protective 
effect may be mediated in part by reducing Myc-dependent 
gene expression. Interestingly, c-Myc has been reported to 
directly activate transcription of the gene encoding αv in 
renal fibroblasts, which in turn increased TGF-β activation 
(Shen et al., 2017). Reduced Myc expression with CWHM-
12 treatment might thus account in part for the observed 
reduction in integrin subunit expression.
While all αv integrins are formally capable of activating 
latent TGF-β by direct binding, they may also have TGF-β-
independent actions on ECM interactions and vasculature 
that support fibrosis (Babic, Chen, & Lau, 1999; Gao, 2006; 
McCurley et al., 2017; Parker et al., 2014). For example, in a 
rat ischemia-reperfusion injury model, specific antibody neu-
tralization of αvβ5 diminished acute renal damage, which was 
correlated with decreased kidney pericyte adhesion, migra-
tion, and vascular permeability (McCurley et al., 2017). The 
pathway analysis of global gene expression also uncovered 
highly significant changes in ECM organization and collagen 
metabolic processes. Independent of the direct biochemical 
role in TGF-β activation, RGD-binding integrins are import-
ant mechanosensors and transducers that provide cells such 
as myofibroblasts and their precursors’ information regard-
ing the components and stiffness of their local ECM (Fiore et 
al., 2018; Lampi & Reinhart-King, 2018; Santos & Lagares, 
2018). There is evidence that fibrotic ECM adapts cells to a 
pro-fibrotic phenotype rather than vice versa (Nagarajan et al., 
F I G U R E  6  (a) Schematic of study design. Daily oral gavage of CWHM-680 (100 mg kg−1 day−1) was started two days prior (day −2) to 
administration of aristolochic acid and continued until study endpoint (day 23). (b) Serum creatinine (sCr mg/dl) in injured (AA) and uninjured 
(PBS) animals that received vehicle or CWHM-680. sCr was decreased at days 7 and 23 in AA-treated animals that received active drug (CWHM-
680) compared with vehicle, although not statistically significantly. PBS + vehicle, n = 5; PBS + CWHM-680, n = 4; AA + vehicle, n = 14; 
AA + CWHM-680, n = 14. (c) mRNA expression was determined by real-time PCR in injured and uninjured control animals treated with CWHM-
680 or vehicle. Relative to uninjured, vehicle-treated animals, the induction of Col1a1 mRNA expression was attenuated in AA-injured animals 
treated with CWHM-680 (38-fold vs. 13-fold, compared with controls. *p = 2.2 × 10−5). Pdgfrb, Acta2, and Fn1 mRNA expression was also 
significantly reduced in injured animals treated with CWHM-680 (*p < .05). AA + vehicle, n = 13; AA + CWHM-680, n = 11. (d) Quantitation of 
collagen deposition by analysis of percent area of kidney sections stained by Sirius red. Relative to vehicle-treated animals, the percent area stained 
by Sirius red was reduced by 52% in AA-injured animals that were treated with CWHM-680. n = 4 biological replicates with at least 36 images 
analyzed for each group, *p = .0005, scale bar = 25 µm. (e) Quantitation of percent area immunostained by PDGFR-β and α-SMA. Relative to 
vehicle-treated animals, the percent area stained for PDGFR-β and SMA was not attenuated in CWHM-680-treated injured animals compared with 
vehicle-treated injured animals. n = 4 with at least 24 images analyzed for each group, scale bar = 50 µm. For b, data were analyzed by two-way 
ANOVA followed by multiple comparison's analysis with Tukey's correction. For c, d, e, and f, data were analyzed by unpaired t-test
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2007). Furthermore, the RGD-containing protein fibronectin, 
which is bound and assembled by integrin α5β1, is robustly 
deposited in remodeling tissue and is essential to collagen ma-
trix deposition and maintenance (Zollinger & Smith, 2017). It 
was recently reported that senescent fibroblasts secrete high 
numbers of extracellular vesicles carrying fibronectin that 
engage α5β1 to confer an invasive phenotype on recipient 
fibroblasts (Chanda et al., 2019). Thus, interference with 
cellular signaling from fibrotic matrix molecules represents 
other mechanisms by which integrin antagonists may miti-
gate myofibroblast differentiation, migration, function, and 
survival. Our RNA-seq data revealed that CWHM-12 treat-
ment downregulated genes that mediate fibronectin binding 
(p = 1.37 × 10–5).
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In conclusion, our preclinical study showed that 
small-molecule RGD peptidomimetic antagonists that tar-
get several pro-fibrotic integrins, including one that was ad-
ministered orally, ameliorated fibrosis and improved renal 
function in a model of nephrotoxicity. Unlike strategies that 
globally inhibit TGF-β, which tend to be limited by side ef-
fects, this approach may be better tolerated due to the unique 
temporal and spatial characteristics of integrin expression at 
sites of injury. The strong correlation of our gene expression 
profiling with studies in humans further supports the clinical 
translational potential of our studies. To advance RGD integ-
rin antagonists to the clinic, future investigation will need to 
determine whether they are effective when given later in the 
course of injury using varied dosing regimens and in differ-
ent injury models. Safety will also need to be confirmed in 
detailed toxicology studies.
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